Overview

Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection

Status:
Unknown status
Trial end date:
2015-11-01
Target enrollment:
0
Participant gender:
All
Summary
In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xiangbei Welman Pharmaceutical Co., Ltd
Treatments:
Piperacillin
Sulbactam
Criteria
Inclusion Criteria:

1. patients who qualify for moderate and severe acute respiratory or urinary tract
bacterial infection of acute bacterial infections need for systemic antibiotic
therapy.

2. Age>18 years old, Gender: both

3. Women of childbearing age were to be negative pregnancy test and agree to take
contraceptive measures during the trial;

4. patients were volunteers and signed informed consent form;

5. patients did not participate in other clinical trials.

Exclusion Criteria:

1. Patients were hypersusceptibility to the test drug or other penicillins ,β-lactamase
inhibitor

2. Pregnant and Lactating women

3. Patients have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and
hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer
or mental illness.

4. Patients who were complicated by other diseases and thought to affect efficacy
evaluations or poor compliance.